Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids
- PMID: 19151123
- DOI: 10.1177/0961203308094995
Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids
Abstract
The aim of this study was to assess the bone mineral density (BMD) of premenopausal patients with systemic lupus erythematosus (SLE) on corticosteroids (CS) and to determine the influence of CS and other risk factors on BMD. A total of 98 premenopausal patients with SLE were recruited from outpatient clinics in two teaching hospitals. Risk factors for osteoporosis were determined, and BMD was measured using dual-energy x-ray absorptiometry. The mean age of the patients was 30.05 +/- 7.54 years. The mean dose of prednisolone at time of BMD measurement was 18.38 +/- 10.85 mg daily. Median duration of CS use was 2.5 years (range 0-20). Median cumulative dose of CS was 9.04 g (range 0.28-890.0). Six patients (6.1%) had osteoporosis, 41 (41.9%) had osteopenia and 51 (52.0%) had normal BMD. Lumbar spine T score correlated with cumulative CS dose (P = 0.019). Duration of CS intake correlated with femoral neck T score (P = 0.04) and trochanter T score (P = 0.008). There was no correlation between BMD and race, SLE Disease Activity Index score, smoking and self-reported calcium intake or exercise. Only 52% of these patients had normal BMD. The duration and cumulative dose of CS intake was significantly correlated to BMD, but not the other commonly assessed risk factors. These findings suggest that premenopausal patients with SLE on CS should have their BMD measured at regular intervals to fully assess their osteoporosis risk.
Similar articles
-
A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus.J Rheumatol. 2008 Dec;35(12):2344-7. doi: 10.3899/jrheum.080634. Epub 2008 Nov 1. J Rheumatol. 2008. PMID: 19004038 Clinical Trial.
-
Four years follow-up of bone mineral density change in premenopausal women with systemic lupus erythematosus.J Med Assoc Thai. 2004 Nov;87(11):1374-9. J Med Assoc Thai. 2004. PMID: 15825716
-
Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus.Arthritis Rheum. 2007 Jun;56(6):1966-73. doi: 10.1002/art.22691. Arthritis Rheum. 2007. PMID: 17530722
-
Osteoporosis risk in premenopausal women.Pharmacotherapy. 2009 Mar;29(3):305-17. doi: 10.1592/phco.29.3.305. Pharmacotherapy. 2009. PMID: 19249949 Review.
-
Osteoporosis in patients with systemic lupus erythematosus.Isr Med Assoc J. 2009 Aug;11(8):486-91. Isr Med Assoc J. 2009. PMID: 19891237 Review.
Cited by
-
Common Variants in OPG Confer Risk to Bone Mineral Density Variation and Osteoporosis Fractures.Sci Rep. 2017 May 11;7(1):1739. doi: 10.1038/s41598-017-01579-6. Sci Rep. 2017. PMID: 28496203 Free PMC article.
-
RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.Osteoporos Int. 2015 May;26(5):1563-71. doi: 10.1007/s00198-015-3029-x. Epub 2015 Jan 22. Osteoporos Int. 2015. PMID: 25609157
-
Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only.Osteoporos Int. 2015 Feb;26(2):601-10. doi: 10.1007/s00198-014-2910-3. Epub 2014 Oct 1. Osteoporos Int. 2015. PMID: 25270396
-
Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients.Osteoporos Int. 2015 Feb;26(2):459-67. doi: 10.1007/s00198-014-2860-9. Epub 2014 Aug 22. Osteoporos Int. 2015. PMID: 25146092
-
High frequency of osteoporosis and fractures in women with dermatomyositis/polymyositis.Rheumatol Int. 2012 Jun;32(6):1549-53. doi: 10.1007/s00296-011-1821-2. Epub 2011 Feb 16. Rheumatol Int. 2012. PMID: 21327426
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical